Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study

키워드

참고문헌 (46)

1. Keller R, "Quality of life in inflammatory bowel diseases : it is not all about the bowel", Intest Res, 19, pp.45~52 (2021)
2. Park SH, "Update on the epidemiology of inflammatory bowel disease in Asia : where are we now?", Intest Res, 20, pp.159~164 (2022)
3. Mowat C, "Guidelines for the management of inflammatory bowel disease in adults", Gut, 60, pp.571~607 (2011)
4. Cohen BL, "Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease", BMJ, 357, pp.j2505~ (2017)
5. Park SH, "Biosimilars : concept, current status, and future perspectives in inflammatory bowel diseases", Intest Res, 18, pp.34~44 (2020)
6. Ooi CJ, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intest Res, 17, pp.285~310 (2019)
7. Na SY, "Korean clinical practice guidelines on biologics and small molecules for moderateto-severe ulcerative colitis", Intest Res, 21, pp.61~87 (2023)
8. Toruner M, "Risk factors for opportunistic infections in patients with inflammatory bowel disease", Gastroenterology, 134, pp.929~936 (2008)
9. Dave M, "Opportunistic infections due to inflammatory bowel disease therapy", Inflamm Bowel Dis, 20, pp.196~212 (2014)
10. Yang H, "Current status of opportunistic infection in inflammatory bowel disease patients in Asia : a questionnaire-based multicenter study", Gut Liver, 16, pp.726~735 (2022)
11. Park S, "Do we have an opportunity to avoid opportunistic infections in Asian patients with inflammatory bowel disease?", Gut Liver, 16, pp.663~664 (2022)
12. Matsuoka K, "Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan : an administrative health claims database analysis", Intest Res, 21, pp.88~99 (2023)
13. Rodriguez M, "Prevention of infection due to Pneumocystis spp. in human immunodeficiency virusnegative immunocompromised patients", Clin Microbiol Rev, 17, pp.770~782 (2004)
14. Avino LJ, "Pneumocystis jirovecii pneumonia in the non-HIV-infected population", Ann Pharmacother, 50, pp.673~679 (2016)
15. Kaur N, "Pneumocystis jiroveci(carinii)pneumonia after infliximab therapy : a review of 84 cases", Dig Dis Sci, 52, pp.1481~1484 (2007)
16. Lawrence SJ, "Pneumocystis jirovecii pneumonia in pediatric inflammatory bowel disease : a case report and literature review", Front Pediatr, 5, pp.161~ (2017)
17. Seddik M, "Pneumocystis jiroveci(carinii)Pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease", Inflamm Bowel Dis, 11, pp.618~620 (2005)
18. Okafor PN, "Costeffectiveness of prophylaxis against Pneumocystis jiroveci pneumonia in patients with Crohn’s disease", Dig Dis Sci, 60, pp.3743~3755 (2015)
19. Okafor PN, "Pneumocystis jiroveci pneumonia in patients with inflammatory bowel disease : a survey of prophylaxis patterns among gastroenterology providers", Inflamm Bowel Dis, 19, pp.812~817 (2013)
20. Cotter TG, "Low risk of pneumonia from Pneumocystis jirovecii infection in patients with inflammatory bowel disease receiving immune suppression", Clin Gastroenterol Hepatol, 15, pp.850~856 (2017)
21. Kucharzik T, "ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease", J Crohns Colitis, 15, pp.879~913 (2021)
22. Long MD, "Increased risk of Pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease", Inflamm Bowel Dis, 19, pp.1018~1024 (2013)
23. Okafor PN, "Pneumocystis jiroveci pneumonia in inflammatory bowel disease : when should prophylaxis be considered?", Inflamm Bowel Dis, 19, pp.1764~1771 (2013)
24. Nam K, "Incidence and risk factors of Pneumocystis jirovecii pneumonia in Korean patients with inflammatory bowel disease", J Gastroenterol Hepatol, 35, pp.218~224 (2020)
25. Song SO, "Background and data configuration process of a nationwide population-based study using the Korean National Health Insurance System", Diabetes Metab J, 38, pp.395~403 (2014)
26. Park S, "Patients with inflammatory bowel disease are at an increased risk of Parkinson’s disease : a South Korean nationwide population-based study", J Clin Med, 8, pp.1191~ (2019)
27. Choi K, "Risk of anxiety and depression in patients with inflammatory bowel disease : a nationwide, population-based study", J Clin Med, 8, pp.654~ (2019)
28. Soh H, "Atopic diseases are associated with development of inflammatory bowel diseases in Korea : a nationwide population-based study", Clin Gastroenterol Hepatol, 19, pp.2072~2081 (2021)
29. White PL, "Therapy and management of Pneumocystis jirovecii infection", J Fungi(Basel), 4, pp.127~ (2018)
30. Mansharamani NG, "Peripheral blood CD4 + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection", Chest, 118, pp.712~720 (2000)
31. Harigai M, "Pneumocystis pneumonia associated with infliximab in Japan", N Engl J Med, 357, pp.1874~1876 (2007)
32. Komano Y, "Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab : a retrospective review and case-control study of 21 patients", Arthritis Rheum, 61, pp.305~312 (2009)
33. Casqueiro J, "Infections in patients with diabetes mellitus : a review of pathogenesis", Indian J Endocrinol Metab, 16(Suppl 1), pp.S27~S36 (2012)
34. Raftery AL, "Links between inflammatory bowel disease and chronic obstructive pulmonary disease", Front Immunol, 11, pp.2144~ (2020)
35. Schuijt TJ, "The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia", Gut, 65, pp.575~583 (2016)
36. Sun Z, "Dynamic changes of gut and lung microorganisms during chronic obstructive pulmonary disease exacerbations", Kaohsiung J Med Sci, 36, pp.107~113 (2020)
37. Labarca G, "Association between inflammatory bowel disease and chronic obstructive pulmonary disease : a systematic review and meta-analysis", BMC Pulm Med, 19, pp.186~ (2019)
38. Lee J, "Risk of inflammatory bowel disease in patients with chronic obstructive pulmonary disease : a nationwide, population-based study", World J Gastroenterol, 25, pp.6354~6364 (2019)
39. Esper AM, "The role of infection and comorbidity : factors that influence disparities in sepsis", Crit Care Med, 34, pp.2576~2582 (2006)
40. Yale SH, "Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome : associated illness and prior corticosteroid therapy", Mayo Clin Proc, 71, pp.5~13 (1996)
41. Escher M, "Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis : a need for prophylaxis", J Crohns Colitis, 4, pp.606~609 (2010)
42. Scott AM, "Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature", Dis Colon Rectum, 40, pp.973~976 (1997)
43. Velayos FS, "Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn’s disease", Inflamm Bowel Dis, 10, pp.657~660 (2004)
44. Yoshida A, "Risk factors for mortality in Pneumocystis jirovecii pneumonia in patients with inflammatory bowel disease", Inflamm Intest Dis, 3, pp.167~172 (2019)
45. Roblot F, "Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients", Eur J Clin Microbiol Infect Dis, 21, pp.523~531 (2002)
46. Sowden E, "Autoimmune inflammatory disorders, systemic corticosteroids and Pneumocystis pneumonia : a strategy for prevention", BMC Infect Dis, 4, pp.42~ (2004)

관련 논문AI추천